Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
5.225 EUR | -0.19% | -5.52% | -21.31% |
Apr. 03 | Nanobiotix completes escalation portion of 2020-0123 study | CF |
Apr. 02 | Nanobiotix Completes Dose Escalation Segment of Phase 1 Study Targeting Non-Small Cell Lung Cancer | MT |
- Stock Market
- Equities
- NANO Stock
- News Nanobiotix